Sorrento Therapeutics Inc. is planning to buy Igdrasol, a private company that develops cancer-treatment products.

Fountain Valley, Calif.-based Igdrasol’s products treat metastic breast cancer, non-small lung cancer and other cancers. The company’s Cynviloq product can inject medication into tumors. Cynviloq is approved in South Korea, and has completed Phase 2 testing in the U.S.

Sorrento, headquartered in San Diego, is a development stage biopharmaceutical company that focuses on developing and commercializing medicines to treat cancer, inflammation and metabolic and infection diseases. Terms of the deal were not disclosed.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.